CD14+ HLA-DR-/low MDSCs are elevated in the periphery of early-stage breast cancer patients and suppress autologous T cell proliferation (Q46243184)

20 December 2017

http://europepmc.org/abstract/MED/29230664

title

CD14+ HLA-DR-/low MDSCs are elevated in the periphery of early-stage breast cancer patients and suppress autologous T cell proliferation (English)

1 reference

20 December 2017

http://europepmc.org/abstract/MED/29230664

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29230664%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Graham Pawelec

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29230664%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Jithendra Kini Bailur

object named as

Jithendra Kini Bailur

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29230664%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Lisa Speigl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29230664%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Helen Burow

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29230664%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Nicole Janssen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29230664%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Christina-Barbara Walter

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29230664%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

language of work or name

English

0 references

publication date

11 December 2017

1 reference

20 December 2017

http://europepmc.org/abstract/MED/29230664

published in

Breast Cancer Research and Treatment

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29230664%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

volume

168

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29230664%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29230664%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

page(s)

401-411

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29230664%20AND%20SRC:MED&resulttype=core&format=json

Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer

12 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

Myeloid-derived suppressor cells as intruders and targets: clinical implications in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

ROS function in redox signaling and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

TGF-β Function in Immune Suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

Role of Stat3 in suppressing anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

A clinical and biological perspective of human myeloid-derived suppressor cells in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

CD15+/CD16low human granulocytes from terminal cancer patients: granulocytic myeloid-derived suppressor cells that have suppressive function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

Noncanonical NF-κB activation mediates STAT3-stimulated IDO upregulation in myeloid-derived suppressor cells in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

Myeloid cells in circulation and tumor microenvironment of breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

Systemic Monocytic-MDSCs Are Generated from Monocytes and Correlate with Disease Progression in Breast Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

Presence of circulating Her2-reactive CD8 + T-cells is associated with lower frequencies of myeloid-derived suppressor cells and regulatory T cells, and better survival in older breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

Reduced oxygen tension results in reduced human T cell proliferation and increased intracellular oxidative damage and susceptibility to apoptosis upon activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

Tumor-dependent down-regulation of the ζ-chain in T-cells is detectable in early breast cancer and correlates with immune cell function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

Tumor-induced changes in the phenotype of blood-derived and tumor-associated T cells of early stage breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

Bio-HMGB1 from breast cancer contributes to M-MDSC differentiation from bone marrow progenitor cells and facilitates conversion of monocytes into MDSC-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4594-9

10.1007/S10549-017-4594-9

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29230664%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29230664%20AND%20SRC:MED&resulttype=core&format=json